| Case 1 | Case 2 | Case 3 |
---|---|---|---|
Age on diagnosis (years) | 52 | 55 | 53 |
Pathological diagnosis | SC | SC | SC |
Stage | IB3 | IIA2 | IB3 |
Primary tumor diameter (maximum, cm) | 6.35 | 5.3 | 5.9 |
Before NACT | |||
 PD-L1 status | positive | positive | positive |
 SCC-Ag (ng/ml) | 26.9 | 6.7 | 8.8 |
 Cytokeratin-19-fragment (ng/ml) | 3.93 | 3.41 | 6.38 |
 Neutrophil/Lymphocyte | 3.54 | 1.94 | 2.47 |
 Platelet/Lymphocyte | 304.2 | 131.47 | 165.33 |
 SIRI = Neutrophil × Monocytes | 0.61 | 0.58 | 1.78 |
Pre-surgery | |||
 SCC-Ag (ng/ml) | 0.6 | 0.8 | 1.5 |
 Cytokeratin-19-fragment (ng/ml) | 0.76 | 0.99 | 1.43 |
 Neutrophil/Lymphocyte | 6.36 | 11.84 | 1.63 |
 Platelet/Lymphocyte | 160.24 | 90.91 | 109.27 |
 SIRI = Neutrophil × Monocytes | 2.06 | 5.86 | 1.16 |
 NACT + ICI (dosage) | Nab-P (260 mg/m2), T (AUC6), Sin (200 mg) | P (135 mg/m2), T (AUC6), Sin (200 mg) | P (135 mg/m2), T (AUC6), Sin (200 mg) |
 Courses | 2 | 2 | 2 |
 Response to NACT | pCR | pPR | pPR |
 Type of surgery | RH + BS + PLND + PALND | RH + BS + PLND + PALND | RH + BS + PLND + PALND |
 Postoperative treatment | CT + ICI | CRT | CRT |
 Follow up (mo) | 22 | 16 | 16 |
 Grade 3–4 adverse events | Myelosuppression (Grade 3) | Leukopenia (Grade 3) | Hypocalcemia, Leukopenia (Grade 3) |